Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Agilon Health (AGL) EBITDA Margin (2020 - 2025)

Agilon Health's EBITDA Margin history spans 6 years, with the latest figure at 12.99% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 541.0% year-over-year to 12.99%; the TTM value through Dec 2025 reached 7.78%, down 299.0%, while the annual FY2025 figure was 7.78%, 299.0% down from the prior year.
  • EBITDA Margin reached 12.99% in Q4 2025 per AGL's latest filing, down from 8.88% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 0.2% in Q1 2023 to a low of 59.68% in Q2 2021.
  • Average EBITDA Margin over 5 years is 9.04%, with a median of 5.81% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: tumbled -5942bps in 2021, then soared 5663bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 17.02% in 2021, then increased by 16bps to 14.3% in 2022, then decreased by -11bps to 15.92% in 2023, then surged by 52bps to 7.57% in 2024, then crashed by -71bps to 12.99% in 2025.
  • Per Business Quant, the three most recent readings for AGL's EBITDA Margin are 12.99% (Q4 2025), 8.88% (Q3 2025), and 8.04% (Q2 2025).